Semaglutide vs Tirzepatide vs Retatrutide: Complete Comparison
How Do These Medications Work?
Single GLP-1 receptor agonists like Semaglutide (active ingredient in Ozempic/Wegovy) delay gastric emptying and trigger satiety in the brain. Tirzepatide (Mounjaro/Zepbound) adds GIP receptor agonism to further control blood glucose and lipid metabolism. Retatrutide represents the next generation—a triple agonist adding glucagon receptor activation, which remarkably elevates resting energy expenditure (calorie burning).
Weight Loss: Head-to-Head Clinical Trial Data
Looking directly at isolated clinical trial benchmarks, absolute efficacy significantly ramps up with each agonist added:
- STEP-1 (Semaglutide): ~14.9% decline across 68 weeks.
- SURMOUNT-1 (Tirzepatid): ~22.5% loss over 72 weeks.
- TRIUMPH-4 (Retatrutid): Average of 28.7% at the 12mg maintenance dose.
Side Effects Compared
Gastrointestinal distress spans the class. Tirzepatide typically demonstrates slightly higher overall tolerability profiles specifically for nausea and vomiting in broader samples. Retatrutide carries similar profiles to semaglutide but with an added novel effect of dysesthesia (cutaneous numbness or tingling) reported in ~20%.
Liver and Cardiovascular Benefits
Wait to switch for MASH resolution? Retatrutide resolved up to 86% of excess liver fat in trials. However, if your history demands cardiovascular fortification, Semaglutide is heavily proven, yielding a 20% reduction in Major Adverse Cardiac Events (MACE) per the SELECT trial—a metric the other pipelines are still gathering.
Frequently Asked Questions
Is retatrutide better than semaglutide?
In clinical trials, retatrutide produced nearly double the weight loss of semaglutide (28.7% vs 14.9%).
Can I switch from Ozempic to retatrutide?
When retatrutide becomes available, switching may be an option following clinical titration protocols.
Which GLP-1 medication has the fewest side effects?
Tirzepatide generally has relatively lower rates of nausea and vomiting among the trialed drugs.
Disclaimer:
This tool is for educational and informational purposes only. It does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA or EMA. Always consult your healthcare provider before starting or modifying any medication.